BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23884473)

  • 1. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
    Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
    Support Care Cancer; 2013 Dec; 21(12):3279-86. PubMed ID: 23884473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
    Oster G; Lamerato L; Glass AG; Richert-Boe KE; Lopez A; Chung K; Richhariya A; Dodge T; Wolff GG; Balakumaran A; Edelsberg J
    Support Care Cancer; 2014 May; 22(5):1363-73. PubMed ID: 24389827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study.
    Baek YH; Jeon HL; Oh IS; Yang H; Park J; Shin JY
    Cancer Epidemiol; 2019 Aug; 61():104-110. PubMed ID: 31176960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.
    Jensen AØ; Jacobsen JB; Nørgaard M; Yong M; Fryzek JP; Sørensen HT
    BMC Cancer; 2011 Jan; 11():29. PubMed ID: 21261987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    Hong S; Youk T; Lee SJ; Kim KM; Vajdic CM
    PLoS One; 2020; 15(7):e0234927. PubMed ID: 32678818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer.
    Barlev A; Song X; Ivanov B; Setty V; Chung K
    J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
    Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
    Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer.
    Hagiwara M; Delea TE; Cong Z; Chung K
    Support Care Cancer; 2014 Jan; 22(1):103-13. PubMed ID: 24000042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
    Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health resource utilization associated with skeletal-related events: results from a retrospective European study.
    Body JJ; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
    Eur J Health Econ; 2016 Jul; 17(6):711-21. PubMed ID: 26253584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
    Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
    Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.
    Hussain A; Aly A; Daniel Mullins C; Qian Y; Arellano J; Onukwugha E
    Cancer Med; 2016 Nov; 5(11):3300-3309. PubMed ID: 27730756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
    Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
    J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spine-specific skeletal related events and mortality in non-small cell lung cancer patients: a single-institution analysis.
    Adogwa O; Rubio DR; Buchowski JM; D'Souza A; Shlykov MA; Jennings JW
    J Neurosurg Spine; 2022 Jan; 36(1):125-132. PubMed ID: 33254136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of bone-targeting agents use in patients with bone metastasis from breast, lung or prostate cancer using structured and unstructured electronic health records from a regional UK-based hospital.
    Seesaghur A; Egger P; Warden J; Abbasi A; Levick B; Riaz M; McMahon P; Thompson M; Cheeseman S
    BMJ Open; 2023 May; 13(5):e069214. PubMed ID: 37156580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain.
    Pockett RD; Castellano D; McEwan P; Oglesby A; Barber BL; Chung K
    Eur J Cancer Care (Engl); 2010 Nov; 19(6):755-60. PubMed ID: 19708928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
    Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
    Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.